专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110308711A1 METHOD AND SYSTEM FOR FORMING A COMPLEX MONOLITHIC THERMOSET PART 有权
标题翻译：用于形成复合单片热电偶部件的方法和系统
公开(公告)号：US20110308711A1
公开(公告)日：2011-12-22
申请号：US12816568
申请日：2010-06-16
申请人： Robert Alexander Coleman , Timothy Dean King , Steven Fillmore Hanson , Leonard Lloyd Baca
发明人： Robert Alexander Coleman , Timothy Dean King , Steven Fillmore Hanson , Leonard Lloyd Baca
IPC分类号： B29C53/50
CPC分类号： B29C33/448 , B29C33/3842 , B29C70/443 , B29C70/446 , B29L2031/737
摘要： A system and method for forming a hollow, complex, monolithic composite part. Composite material may be placed around the mandrel, then an internal impermeable membrane may be placed into and/or through tunnels formed in the mandrel. Next, an external impermeable membrane may be placed around the composite material and sealed against itself and the internal impermeable membrane such that the mandrel and the composite material are both contained in an airtight manner between the internal and external impermeable membranes. Air may then be removed from within the sealed impermeable membranes, compressing the impermeable membranes against the mandrel and/or the composite material. The consolidated composite material may be hardened to form the composite part. Finally, the impermeable membrane may be removed from around the hollow composite part and from within the mandrel, followed by removal of the mandrel from within the composite part by breaking it up into smaller pieces.
摘要翻译：一种用于形成中空复合整体复合材料部件的系统和方法。可以将复合材料放置在心轴周围，然后将内部不可渗透的膜放置在形成在心轴中的通道中和/或穿过该通孔中。接下来，外部不可渗透的膜可以放置在复合材料周围并且被密封抵抗其自身和内部不可渗透的膜，使得心轴和复合材料都以内部和外部不可渗透膜之间的气密方式包含。然后可以从密封的不可渗透膜中除去空气，将不透水膜压靠在心轴和/或复合材料上。固结的复合材料可以被硬化以形成复合部件。最后，不可渗透的膜可以从中空复合材料部件周围和芯棒内部移除，然后通过将其分解成较小的部件从复合材料部件中除去心轴。

2. 发明授权

US08080567B2 EP2 receptor agonists 失效
标题翻译： EP2受体激动剂
公开(公告)号：US08080567B2
公开(公告)日：2011-12-20
申请号：US12063421
申请日：2006-08-09
申请人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Shirley Ann Brunton , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd
发明人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Shirley Ann Brunton , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd
IPC分类号： A61K31/44 , A61K31/42 , A61K31/195
CPC分类号： C07C233/81 , C07C257/18 , C07D213/70 , C07D263/57 , C07D307/42 , C07D307/54 , C07D307/68 , C07D307/91 , C07D405/12
摘要： A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formula (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formula (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formula (A) (B) where RP6 is selected from fluoro and chloro; and R2 is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.
摘要翻译：式（III）化合物或其盐，溶剂化物和化学保护形式，其中：R 5为任选取代的C 5-20芳基或C 4-20烷基; L'是单键，-O-或-C（= O） - ; A选自：式（i）（ii）（iii）其中X和Y选自：O和CR 3; S和CR3; NH和CR3; NH和N; O和N; S和N; N和S; 和N和O，并且其中虚线表示适当位置的双键，并且其中Q为N或CH; D选自：式（i）（ii）（iii）（iv）（v）（vii）（viii）（ix）B选自：其中选择RP6的式（A）（B）来自氟和氯; 并且R2是：（i）-CO 2 H; （ii）-CONH 2; （ⅲ）-CH 2 -OH; 或（iv）四唑-5-基。

3. 发明授权

US07803841B2 EP2 receptor agonists 失效
标题翻译： EP2受体激动剂
公开(公告)号：US07803841B2
公开(公告)日：2010-09-28
申请号：US12346516
申请日：2008-12-30
申请人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd , Shirley Ann Brunton
发明人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd , Shirley Ann Brunton
IPC分类号： A61K31/166 , C07C233/65
CPC分类号： C07D213/81 , C07C233/75 , C07C233/81 , C07C235/84 , C07D233/90 , C07D257/04 , C07D277/24 , C07D277/26 , C07D277/56 , C07D307/46 , C07D307/68 , C07D307/91 , C07D333/38 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12
摘要： The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.
摘要翻译：本公开提供EP2受体激动剂化合物和使用该化合物治疗可通过EP2受体激动作用缓解的病症的方法。

4. 发明申请

US20090298899A1 EP2 RECEPTOR AGONISTS 失效
标题翻译： EP2受体激素
公开(公告)号：US20090298899A1
公开(公告)日：2009-12-03
申请号：US12346516
申请日：2008-12-30
申请人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd , Shirley Ann Brunton
发明人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd , Shirley Ann Brunton
IPC分类号： A61K31/395 , C07D307/68 , C07D257/04 , A61P27/06 , A61K31/34
CPC分类号： C07D213/81 , C07C233/75 , C07C233/81 , C07C235/84 , C07D233/90 , C07D257/04 , C07D277/24 , C07D277/26 , C07D277/56 , C07D307/46 , C07D307/68 , C07D307/91 , C07D333/38 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12
摘要： The disclosure provides EP2 receptor agonist compounds and methods for using the compounds for treating conditions which can be alleviated by agonism of an EP2 receptor.
摘要翻译：本公开提供EP2受体激动剂化合物和使用该化合物治疗可通过EP2受体激动作用缓解的病症的方法。

5. 发明授权

US07429607B2 5-HT2B receptor antagonists 失效
标题翻译： 5-HT2B受体拮抗剂
公开(公告)号：US07429607B2
公开(公告)日：2008-09-30
申请号：US10364672
申请日：2003-02-12
申请人： Alexander William Oxford , Richard Anthony Borman , Robert Alexander Coleman , Kenneth Lyle Clark , George Hynd , Janet Ann Archer , Amanda Aley , Neil Victor Harris
发明人： Alexander William Oxford , Richard Anthony Borman , Robert Alexander Coleman , Kenneth Lyle Clark , George Hynd , Janet Ann Archer , Amanda Aley , Neil Victor Harris
IPC分类号： A61K31/42 , A61K31/445 , A61K31/55 , C07D263/00 , C07D413/00 , C07D419/00 , C07D403/00
CPC分类号： C07D413/04 , C07D263/48
摘要： The present invention relates to compounds of formula I: wherein one of R1 and R4 is selected from the group consisting of H, and optionally substituted C1-6 alkyl, C3-7 cycloalkyl, C3-7 cycloalkyl-C1-4 alkyl, and phenyl-C1-4 alkyl; and the other of R1 and R4 is an optionally substituted C9-14 aryl group; R2 and R3 are either: (i) independently selected from H, R, R′, SO2R, C(═O)R, (CH2)nNR5R6, where n is from 1 to 4 and R5 and R6 are independently selected from H and R, where R is optionally substituted C1-4 alkyl, and R′ is optionally substituted phenyl-C1-4 alkyl, or (ii) together with the nitrogen atom to which they are attached, form an optionally substituted C5-7 heterocyclic group; and their use as pharmaceuticals, in particular for treating conditions alleviated by the antagonism of a 5-HT2B receptor.
摘要翻译：本发明涉及式I化合物：其中R 1和R 4中的一个选自H和任选取代的C 1〜 C 6 -C 12烷基，C 3-7环烷基，C 3-7环烷基-C 1-4烷基和苯基-C 1-4个C 1-4烷基; R 1和R 4中的另一个是任选取代的C 9-14芳基; R 2和R 3是：（i）独立地选自H，R，R'，SO 2 R，C（-O ）R，（CH 2）2 NR 6，其中n为1至4，R H和R 6独立地选自H和R，其中R是任选取代的C 1-4烷基，R'任选被取代苯基-C 1-4烷基，或（ii）与它们所连接的氮原子一起形成任选取代的C 5-7杂环基; 以及它们作为药物的用途，特别是用于治疗由5-HT 2B受体拮抗而缓解的病症。

6. 发明申请

US20080119526A1 EP2 RECEPTOR AGONISTS 失效
公开(公告)号：US20080119526A1
公开(公告)日：2008-05-22
申请号：US11950613
申请日：2007-12-05
申请人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd , Shirley Ann Brunton
发明人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd , Shirley Ann Brunton
IPC分类号： A61K31/4418 , C07D307/66 , A61K31/341 , A61P27/06 , A61P19/08 , A61P37/00 , A61P43/00 , C07D213/78
CPC分类号： C07D213/81 , C07C233/75 , C07C233/81 , C07C235/84 , C07D233/90 , C07D257/04 , C07D277/24 , C07D277/26 , C07D277/56 , C07D307/46 , C07D307/68 , C07D307/91 , C07D333/38 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12
摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN′ is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and the other of RP3 and RP4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when RP3 is —Cm alkylene-R2, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R2 is tetrazol-5-yl, m+n may be 0; or where one of RP3 and RP4 is —O—CH2—R2, and the other of RP3 and RP4 is H, n is 0; RN is H or optionally substituted C1-4 alkyl; R2 is either: —CO2H (carboxy); —CONH2; —CH2—OH; or tetrazol-5-yl.

7. 发明授权

US08377248B2 Method and system for forming a complex monolithic thermoset part 有权
标题翻译：用于形成复合单片热固性部件的方法和系统
公开(公告)号：US08377248B2
公开(公告)日：2013-02-19
申请号：US12816568
申请日：2010-06-16
申请人： Robert Alexander Coleman , Timothy Dean King , Steven Fillmore Hanson , Leonard Lloyd Baca
发明人： Robert Alexander Coleman , Timothy Dean King , Steven Fillmore Hanson , Leonard Lloyd Baca
IPC分类号： B29C65/00 , B32B37/00
CPC分类号： B29C33/448 , B29C33/3842 , B29C70/443 , B29C70/446 , B29L2031/737
摘要： A system and method for forming a hollow, complex, monolithic composite part. Composite material may be placed around the mandrel, then an internal impermeable membrane may be placed into and/or through tunnels formed in the mandrel. Next, an external impermeable membrane may be placed around the composite material and sealed against itself and the internal impermeable membrane such that the mandrel and the composite material are both contained in an airtight manner between the internal and external impermeable membranes. Air may then be removed from within the sealed impermeable membranes, compressing the impermeable membranes against the mandrel and/or the composite material. The consolidated composite material may be hardened to form the composite part. Finally, the impermeable membrane may be removed from around the hollow composite part and from within the mandrel, followed by removal of the mandrel from within the composite part by breaking it up into smaller pieces.
摘要翻译：一种用于形成中空复合整体复合材料部件的系统和方法。可以将复合材料放置在心轴周围，然后将内部不可渗透的膜放置在形成在心轴中的通道中和/或穿过该通孔中。接下来，外部不可渗透的膜可以放置在复合材料周围并且被密封抵抗其自身和内部不可渗透的膜，使得心轴和复合材料都以内部和外部不可渗透膜之间的气密方式包含。然后可以从密封的不可渗透膜中除去空气，将不透水膜压靠在心轴和/或复合材料上。固结的复合材料可以被硬化以形成复合部件。最后，不可渗透的膜可以从中空复合材料部件周围和芯棒内部移除，然后通过将其分解成较小的部件从复合材料部件中除去心轴。

8. 发明授权

US07417068B2 EP4 receptor antagonists 失效
标题翻译： EP4受体拮抗剂
公开(公告)号：US07417068B2
公开(公告)日：2008-08-26
申请号：US10964831
申请日：2004-10-15
申请人： David Edward Clark , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark
发明人： David Edward Clark , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark
IPC分类号： A61K31/341 , C07D307/34
CPC分类号： C07D307/68
摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein one of R2 and R5 is: (i) H or an optionally substituted C1-4 alkyl group; or (ii)an optionally substituted C5-7 aryl; and the other of R2 and R5 is the other group; m and n can be 0 or 1, and m+n=1 or 2 RN is H or optionally substituted C1-4 alkyl R3 is either: (i) carboxy; (ii) a group of formula (II): (iii) a group of formula (III): wherein R is optionally substituted C1-7 alkyl, C5-20 aryl, or NRN3RN4, where RN3 and RN4 are independently selected from optionally substituted C1-4 alkyl; or (iv) tetrazol-5-yl.
摘要翻译：式（I）化合物或其盐，溶剂合物和化学保护形式，其中R 2和R 5中的一个为：（i）H或任选地取代的C 1-4烷基; 或（ii）任选取代的C 5-7芳基; R 2和R 5中的另一个是另一个基团; m和n可以是0或1，m + n = 1或2 R N是H或任选取代的C 1-4烷基R 3， SUP>是：（i）羧基; （ii）式（II）的基团：（iii）式（III）的基团：其中R是任选取代的C 1-7烷基，C 5〜20 其中R 3，N 3和R 4各自独立地选自任选取代的C 1 -C 6芳基或NR N 3 N， 1-4个C 1-4烷基; 或（iv）四唑-5-基。

9. 发明授权

US07326732B2 EP2 receptor agonists 失效
公开(公告)号：US07326732B2
公开(公告)日：2008-02-05
申请号：US11055724
申请日：2005-02-11
申请人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd , Shirley Ann Brunton
发明人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd , Shirley Ann Brunton
IPC分类号： C07C233/65 , C07D257/04 , A61K31/41 , A61K31/164
CPC分类号： C07D213/81 , C07C233/75 , C07C233/81 , C07C235/84 , C07D233/90 , C07D257/04 , C07D277/24 , C07D277/26 , C07D277/56 , C07D307/46 , C07D307/68 , C07D307/91 , C07D333/38 , C07D401/12 , C07D405/04 , C07D405/12 , C07D409/12
摘要： A compound of formula (I): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20 alkyl group; A is selected from the group consisting of: wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; R3 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R4 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; R6 is selected from H, F, Cl and optionally substituted C1-4 alkyl, C1-4 alkoxy, C5-7 aryl and C5-7 aryl-C1-4 alkyl groups; D is selected from: B is selected from the group consisting of: where RN′ is selected from H and C1-4 alkyl; where one of RP3 and RP4 is —Cm alkylene-R2 and the other of RP3 and RP4 is H, m and n can be 0 or 1, and m+n=1 or 2; and additionally when RP3 is —Cm alkylene-R2, m can also be 2 or 3, and m+n=1, 2, 3 or 4, and when R2 is tetrazol-5-yl, m+n may be 0; or where one of RP3 and RP4 is —O—CH2—R2, and the other of RP3 and RP4 is H, n is 0; RN is H or optionally substituted C1-4 alkyl; R2 is either: —CO2H (carboxy); —CONH2; —CH2—OH; or tetrazol-5-yl.

10. 发明申请

US20100130556A1 EP2 RECEPTOR AGONISTS 失效
标题翻译： EP2受体激素
公开(公告)号：US20100130556A1
公开(公告)日：2010-05-27
申请号：US12063421
申请日：2006-08-09
申请人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Shirley Ann Brunton , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd
发明人： Alexander William Oxford , Richard Jon Davis , Robert Alexander Coleman , Kenneth Lyle Clark , David Edward Clark , Shirley Ann Brunton , Neil Victor Harris , Garry Fenton , George Hynd , Keith Alfred James Stuttle , Jonathan Mark Sutton , Mark Richard Ashton , Edward Andrew Boyd
IPC分类号： A61K31/443 , C07C249/00 , A61K31/195 , C07C229/40 , C07D307/02 , A61K31/341 , C07D405/12 , C07D263/56 , A61K31/423
CPC分类号： C07C233/81 , C07C257/18 , C07D213/70 , C07D263/57 , C07D307/42 , C07D307/54 , C07D307/68 , C07D307/91 , C07D405/12
摘要： A compound of formula (III): or a salt, solvate and chemically protected form thereof, wherein: R5 is an optionally substituted C5-20 aryl or C4-20alkyl group; L′ is a single bond, —O— or —C(═O)—; A is selected from the group consisting of: formulae (i) (ii) (iii) wherein X and Y are selected from the group consisting of: O and CR3; S and CR3; NH and CR3; NH and N; O and N; S and N; N and S; and N and O, and where the dotted lines indicate a double bond in the appropriate location, and where Q is either N or CH; D is selected from: formulae (i) (ii) (iii) (iv) (v) (vii) (viii) (ix) B is selected from the group consisting of: formulae (A) (B) where RP6 is selected from fluoro and chloro; and R2 is either: (i) —CO2H; (ii) —CONH2; (iii) —CH2—OH; or (iv) tetrazol-5-yl.
摘要翻译：式（III）化合物或其盐，溶剂化物和化学保护形式，其中：R 5为任选取代的C 5-20芳基或C 4-20烷基; L'是单键，-O-或-C（= O） - ; A选自：式（ⅰ）（ⅱ）（ⅲ）其中X和Y选自：O和CR 3; S和CR3; NH和CR3; NH和N; O和N; S和N; N和S; 和N和O，并且其中虚线表示适当位置的双键，并且其中Q为N或CH; D选自：式（i）（ii）（iii）（iv）（v）（vii）（viii）（ix）B选自：其中选择RP6的式（A）（B）来自氟和氯; 并且R2是：（i）-CO 2 H; （ii）-CONH 2; （ⅲ）-CH 2 -OH; 或（iv）四唑-5-基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式